TY - JOUR
T1 - A survey of risk tolerance to multiple sclerosis therapies
AU - Fox, Robert J.
AU - Cosenza, Carol
AU - Cripps, Lauren
AU - Ford, Paul
AU - Mercer, Mary Beth
AU - Natarajan, Sneha
AU - Salter, Amber
AU - Tyry, Tuula
AU - Cofield, Stacey S.
N1 - Publisher Copyright:
© American Academy of Neurology.
PY - 2019/4/2
Y1 - 2019/4/2
N2 - ObjectiveTo determine tolerance to various risk scenarios associated with current multiple sclerosis (MS) therapies.MethodsPeople with MS from the North American Research Committee on Multiple Sclerosis Registry's online cohort and the National Multiple Sclerosis Society were invited to complete a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple risks levels were presented, including skin rash, infection, kidney injury, thyroid injury, liver injury, and progressive multifocal leukoencephalopathy (PML).ResultsBoth PML and kidney injury had the lowest risk tolerance (RT) at 1:1,000,000, and thyroid and infection risks had the highest tolerance at 1:1,000. Men, younger individuals, and participants with greater disability reported a higher tolerance to all risk scenarios. Those who were currently taking an MS therapy reported higher tolerance than those not taking any therapy. Participants taking infusion therapies reported high tolerance to all risks, and those taking injectables reported a lower tolerance.ConclusionPeople with MS displayed a wide range of RT for MS therapies. Our study identified sex, age, disability, and current disease-modifying therapy use to be associated with RT.
AB - ObjectiveTo determine tolerance to various risk scenarios associated with current multiple sclerosis (MS) therapies.MethodsPeople with MS from the North American Research Committee on Multiple Sclerosis Registry's online cohort and the National Multiple Sclerosis Society were invited to complete a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple risks levels were presented, including skin rash, infection, kidney injury, thyroid injury, liver injury, and progressive multifocal leukoencephalopathy (PML).ResultsBoth PML and kidney injury had the lowest risk tolerance (RT) at 1:1,000,000, and thyroid and infection risks had the highest tolerance at 1:1,000. Men, younger individuals, and participants with greater disability reported a higher tolerance to all risk scenarios. Those who were currently taking an MS therapy reported higher tolerance than those not taking any therapy. Participants taking infusion therapies reported high tolerance to all risks, and those taking injectables reported a lower tolerance.ConclusionPeople with MS displayed a wide range of RT for MS therapies. Our study identified sex, age, disability, and current disease-modifying therapy use to be associated with RT.
UR - http://www.scopus.com/inward/record.url?scp=85064199140&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000007245
DO - 10.1212/WNL.0000000000007245
M3 - Article
C2 - 30867272
AN - SCOPUS:85064199140
SN - 0028-3878
VL - 92
SP - E1634-E1642
JO - Neurology
JF - Neurology
IS - 14
ER -